Artikelen door HollandBIO

,

Nederlandse vestigingsklimaat in de lift

Het vertrouwen van internationale investeerders in het Nederlandse vestigingsklimaat is het afgelopen jaar verder toegenomen. Dat is een van de conclusies van de EY barometer Nederlands vestigingsklimaat 2018. Daarbovenop bevestigt een recent verschenen rapport van KPMG de rol van Nederland als koploper op het gebied van life sciences. De rapporten maken wederom duidelijk dat het […]

,

Alexion and Complement Pharma co-develop complement inhibitor for neurodegenerative disorders

Alexion and Complement Pharma announced a partnership to co-develop the preclinical C6 complement inhibitor CP010 for neurodegenerative disorders. C6 inhibition prevents the formation of the destructive membrane attack complex (MAC), a complex of terminal complement proteins that mediate cellular injury following complement activation, and has the potential to treat a variety of central nervous system […]

,

Sanofi Pasteur and Translate Bio Launch mRNA Vaccine Partnership

Sanofi’s global vaccines unit Sanofi Pasteur will partner with Translate Bio to develop mRNA vaccines for up to five undisclosed infectious disease pathogens, through a collaboration that the mRNA therapeutics developer said today could generate for it up to $805 million-plus. During the collaboration’s initial three-year research term, Translate Bio said, it will join Sanofi […]

‘Sexy plants’ on track to replace harmful pesticides to protect crops

Researchers are genetically engineering plants to produce the sex pheromones of insects, which then frustrate the pests’ attempts to mate. “Sexy plants” are on the way to replacing many harmful pesticides, scientists say, by producing the sex pheromones of insects which then frustrate pests’ attempts to mate. Scientists have already genetically engineered a plant to […]

AstraZeneca and MSD present new results about Lynparza

The two pharma giants report data which showed clinical improvement in median radiologic progression-free survival (rPFS) with Lynparza (olaparib) in combination with abiraterone compared to abiraterone monotherapy, a standard of care, in metastatic castration-resistant prostate cancer (mCRPC). Lynparza is being jointly developed and commercialised by AstraZeneca and MSD. Phase II trial The results of Study 08, […]

Pfizer unveils $600m investment in venture capital arm

Pfizer is planning to invest $600 million in biotechnology and other emerging growth companies through its venture investment group. Pfizer Ventures will dedicate 25 percent of the funds to neuroscience, seeking out promising early-stage neuroscience companies to support “a broad array of early research and product development opportunities”. “By changing the way we invest in […]

,

Biogen Buys Option to TMS’ Phase II Stroke Candidate

Biogen has acquired an exclusive option to TMS’ Phase II acute stroke candidate TMS-007 and backup compounds through a deal that could generate up to $357 million-plus for the Japanese biotech and is intended to reinforce the buyer’s commitment to stroke drugs by adding a potentially long-acting treatment to its acute neurology portfolio. TMS-007 is […]

Organic insect deterrent for agriculture

Traditional insecticides are killers: they not only kill pests, they also endanger bees and other beneficial insects, as well as affecting biodiversity in soils, lakes, rivers and seas. A team from the Technical University of Munich (TUM) has now developed an alternative: A biodegradable agent that keeps pests at bay without poisoning them. “It’s not […]

,

MDxHealth licensing agreement with Philips facilitates launch InformMDx(TM)

MDxHealth announced a worldwide licensing agreement with Philips for the rights to manufacture and market Philips’ recently validated prognostic biomarker for prostate cancer, phosphodiesterase-4D7 (“PDE4D7”), as a prognostic test. The test is based on technology which was jointly developed by Philips Research and The University of Glasgow. The agreement enables MDxHealth to prepare the launch […]